Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

MNKD – MannKind Corporation

MannKind Corporation
MNKD
$4.11
Name : MannKind Corporation
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $1,261,063,168.00
EPSttm : 0.11
finviz dynamic chart for MNKD
MannKind Corporation
$4.11
4.31%
$0.17

Float Short %

7.97

Margin Of Safety %

5

Put/Call OI Ratio

0.08

EPS Next Q Diff

EPS Last/This Y

0.07

EPS This/Next Y

Price

4.12

Target Price

9.25

Analyst Recom

1

Performance Q

-2.61

Relative Volume

1.03

Beta

1

Ticker: MNKD




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25MNKD4.050.060.1760913
2025-07-28MNKD3.950.060.1361365
2025-07-29MNKD3.810.060.0962197
2025-07-30MNKD3.880.060.1262480
2025-07-31MNKD3.780.060.0662614
2025-08-01MNKD3.750.060.0362720
2025-08-04MNKD3.920.060.0063108
2025-08-05MNKD3.980.060.0063648
2025-08-06MNKD3.470.050.2770302
2025-08-07MNKD3.420.070.4177493
2025-08-08MNKD3.520.070.0377873
2025-08-11MNKD3.420.070.0177734
2025-08-12MNKD3.650.070.0379156
2025-08-13MNKD3.730.070.1680909
2025-08-14MNKD3.710.070.5682156
2025-08-15MNKD3.730.070.1482240
2025-08-18MNKD3.820.090.0360985
2025-08-19MNKD3.970.080.0062383
2025-08-20MNKD3.980.080.0465358
2025-08-21MNKD3.940.080.0065721
2025-08-22MNKD4.110.080.0065742
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25MNKD4.06- - 0.30
2025-07-28MNKD3.95- - 0.29
2025-07-29MNKD3.82- - 0.29
2025-07-30MNKD3.87- - 0.29
2025-07-31MNKD3.78- - 0.29
2025-08-01MNKD3.75- - 0.29
2025-08-04MNKD3.92- - 0.29
2025-08-05MNKD3.99- - 0.29
2025-08-06MNKD3.47- - 0.29
2025-08-07MNKD3.43- - 0.29
2025-08-08MNKD3.5287.5- 0.29
2025-08-11MNKD3.4287.5- 0.29
2025-08-12MNKD3.66-8.3- 0.17
2025-08-13MNKD3.73-8.3- 0.17
2025-08-14MNKD3.71-8.3- 0.17
2025-08-15MNKD3.74-8.3- 0.17
2025-08-18MNKD3.82-8.3- 0.17
2025-08-19MNKD3.96-8.3- 0.17
2025-08-20MNKD3.98-8.3- 0.17
2025-08-21MNKD3.95-8.3- 0.17
2025-08-22MNKD4.12-8.3- 0.17
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25MNKD-3.025.358.05
2025-07-28MNKD-3.025.348.05
2025-07-29MNKD-3.025.348.05
2025-07-30MNKD-3.025.348.05
2025-07-31MNKD-3.025.348.05
2025-08-01MNKD-3.025.348.05
2025-08-04MNKD-3.025.238.05
2025-08-05MNKD-3.025.238.05
2025-08-06MNKD-3.025.238.05
2025-08-07MNKD-3.025.238.05
2025-08-08MNKD-3.025.238.05
2025-08-11MNKD-2.995.217.97
2025-08-12MNKD-2.995.217.97
2025-08-13MNKD-2.995.217.97
2025-08-14MNKD-2.995.217.97
2025-08-15MNKD-2.995.217.97
2025-08-18MNKD-2.993.237.97
2025-08-19MNKD-2.993.237.97
2025-08-20MNKD-2.993.237.97
2025-08-21MNKD-2.993.237.97
2025-08-22MNKD-2.993.237.97
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

0.04

Avg. EPS Est. Next Quarter

0.04

Insider Transactions

-2.99

Institutional Transactions

3.23

Beta

1

Average Sales Estimate Current Quarter

80

Average Sales Estimate Next Quarter

83

Fair Value

4.31

Quality Score

37

Growth Score

75

Sentiment Score

90

Actual DrawDown %

46

Max Drawdown 5-Year %

-57.3

Target Price

9.25

P/E

37.6

Forward P/E

35.35

PEG

1.48

P/S

4.18

P/B

P/Free Cash Flow

44.69

EPS

0.11

Average EPS Est. Cur. Y​

0.17

EPS Next Y. (Est.)

0.18

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

10.87

Relative Volume

1.03

Return on Equity vs Sector %

-84.3

Return on Equity vs Industry %

-71.4

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

-0.17

EBIT Estimation

MannKind Corporation
Sector: Healthcare
Industry: Biotechnology
Employees: 403
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States. It offers Afrezza Inhalation Powder, an inhaled insulin used to improve glycemic control in adults with diabetes; the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults; and Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension. The company's product pipeline includes MNKD-101, a nebulized formulation of clofazimine, which is in Phase 3 study, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, which is in phase 1 clinical study, for the treatment of idiopathic pulmonary fibrosis (IPF); MNKD-301, which is in preclinical stage, for cystic fibrosis; and Pediatric Afrezza, which is in phase 3 clinical trial for the treatment of diabetes mellitus. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India; and co-promotion agreement with Amphastar for marketing of Baqsimi (glucagon) nasal powder. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
stock quote shares MNKD – MannKind Corporation Stock Price stock today
news today MNKD – MannKind Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch MNKD – MannKind Corporation yahoo finance google finance
stock history MNKD – MannKind Corporation invest stock market
stock prices MNKD premarket after hours
ticker MNKD fair value insiders trading